Cleveland BioLabs, Inc. (NASDAQ:CBLI)
CAPS Rating:
The Company is engaged in the discovery, development and commercialization of products for cancer treatment and protection of normal tissues from radiation and toxins.
The Company is engaged in the discovery, development and commercialization of products for cancer treatment and protection of normal tissues from radiation and toxins.
Recs
opportunity after recent overeaction